Recombinant Human EG-VEGF (Animal-Free)
Non-reducing (-) and reducing (+) conditions in a 4 - 20% Tris-Glycine gel stained with Coomassie Blue. 1 μg of protein was loaded in each lane. Human EG-VEGF has a predicted Mw of 9.7 kDa.
Achieve Purchasing Synergy
Request a quote at [email protected] for 2 or more vials of any Growth Factor to receive a discount. Discounts range from 5 to 20% according to the size of your order.
PODS® Growth Factors
The product is currently not available as PODS®, please check back in the future.Animal-Free
This product is produced with no animal derived raw products. All processing and handling employs animal free equipment and animal free protocols.Description
Endocrine Gland-derived Vascular Endothelial Growth Factor (EG-VEGF) is an angiogenic growth factor that is expressed in the ovaries, testis, adrenal, and placental tissues. EG-VEGF has mitogenic, chemoattractive, and antiapoptotic functional roles. EG-VEGF signaling is mediated through binding the G protein-coupled receptors prokineticin receptor 1 (PKR1) and prokineticin receptor 2 (PKR2). Polycystic ovaries display strong EG-VEGF expression that is associated with increased angiogenesis and cyst formation, which could lead to the formation of polycystic ovary syndrome and infertility.Activity Assay
Human EG-VEGF is fully biologically active when compared to standard. The activity is determined by the dose-dependent proliferation of MIA PaCa-2 cells and it is typically 1 - 4 μg/ml. This corresponds to an expected specific activity of 1 x 103 units/mg. There is no data currently available.AA Sequence
AVITGACERD VQCGAGTCCA ISLWLRGLRM CTPLGREGEE CHPGSHKVPF FRKRKHHTCP CLPNLLCSRF PDGRYRCSMD LKNINFAlternative Names
Endocrine Gland-derived Vascular Endothelial Growth Factor, prokineticin 1, PROK1| Product Details | |
|---|---|
| Length | 86 aa |
| Molecular Weight | 9.7 kDa |
| Structure | Monomer |
| Source | E. coli |
| Accession Number | P58294 |
| Purity | ≥95% determined by reducing and non-reducing SDS-PAGE |
| Endotoxin Level | ≤1.00 EU/μg as measured by kinetic LAL |
| Formulation | Lyophilized from a sterile (0.2 micron) filtered aqueous solution containing 0.1% Trifluoroacetic Acid (TFA) |
| Reconstitution | Centrifuge vial before opening. When reconstituting the product, gently pipet and wash down the sides of the vial to ensure full recovery of the protein into solution. It is recommended to reconstitute the lyophilized product with sterile water at 0.1 mg/ml, which can be further diluted into other aqueous solutions. |
| Stability and Storage |
12 months from date of receipt when stored at -20°C to -80°C as supplied. 1 month when stored at 4°C after reconstituting as directed. 3 months when stored at -20°C to -80°C after reconstituting as directed. |
